Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease

Nutrition. 2004 Nov-Dec;20(11-12):974-8. doi: 10.1016/j.nut.2004.08.004.

Abstract

Objective: The polymorphism of the gene encoding methylenetetrahydrofolate reductase (MTHFR) and folic acid nutritional status play important roles in atherosclerosis. The present study investigated the total homocysteine-lowering effect of folic acid in response to the MTHFR genotype in patients who have cardiovascular disease.

Methods: Twenty-three patients who had cardiovascular disease (ages 44 to 88 y) were supplemented with 5 mg of folic acid/d for 8 wk. Blood samples were collected before and after supplementation for the measurement of folic acid. The presence of the 677C-->T mutation was assessed by polymerase chain reaction followed by restriction enzyme analysis.

Results: After the 8 wk of folic acid supplementation, plasma total homocysteine decreased 40% in patients who had the TT genotype, 23% in those who had the CT genotype, 10% in those who had the CC genotype, and 27% in carriers of the T allele. The plasma total homocysteine-lowering effect of folic acid was significant only in patients who had the CT genotype and in carriers of the T allele.

Conclusions: The MTHFR polymorphism may be involved in the total homocysteine-lowering effect of folic acid in patients who have cardiovascular disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Cardiovascular Diseases
  • Dietary Supplements
  • Dose-Response Relationship, Drug
  • Female
  • Folic Acid / administration & dosage*
  • Genotype
  • Homocysteine / blood*
  • Humans
  • Hyperhomocysteinemia / drug therapy*
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Restriction Mapping
  • Treatment Outcome

Substances

  • Homocysteine
  • Folic Acid
  • Methylenetetrahydrofolate Reductase (NADPH2)